Cytochrome P450 epoxygenase (CYP epoxygenase)

Cytochrome P450 (CYP) epoxygenases, primarily including the CYP2C and CYP2J subfamilies (notably CYP2C8, CYP2C9, and CYP2J2), are key enzymes responsible for the production of endothelium-derived hyperpolarizing factors (EDHFs) [1.2.2, 1.3.1]. They catalyze the metabolism of arachidonic acid into epoxyeicosatrienoic acids (EETs), which play a vital role in maintaining vascular homeostasis by inducing smooth muscle hyperpolarization and vasodilation [1.1.3, 1.3.3]. These EETs act by activating large-conductance calcium-activated potassium (BKCa) channels, which is a critical mechanism for blood pressure regulation, especially in the microcirculation [1.3.3, 1.4.4]. Beyond their role in regulating vascular tone, these enzymes and their EET products exhibit potent anti-inflammatory, anti-apoptotic, and cardioprotective properties [1.2.3, 1.4.1]. This makes them attractive therapeutic targets for conditions such as hypertension, coronary artery disease, and myocardial ischemia-reperfusion injury [1.2.3, 1.4.1]. However, pharmacological modulation of these enzymes is complicated by their significant role in xenobiotic metabolism, which poses a risk for drug-drug interactions, particularly with CYP2C9 [1.1.4, 1.2.1]. Additionally, their pro-angiogenic effects, while beneficial for tissue repair, may inadvertently promote tumor growth and metastasis in oncological contexts [1.2.2, 1.4.3]. Furthermore, enzyme uncoupling can lead to the production of reactive oxygen species (ROS), potentially contributing to oxidative stress and endothelial dysfunction [1.2.2, 1.4.2]. Current research focuses on developing selective epoxygenase activators or soluble epoxide hydrolase (sEH) inhibitors to enhance the beneficial effects of the EET pathway [1.2.3, 1.4.1].

Other names

EDHF synthaseArachidonic acid epoxygenaseCytochrome P450 2C8Cytochrome P450 2C9Cytochrome P450 2J2CYP2CCYP2J

Inhibition of epoxygenase activity to reduce EET-mediated effects (e.g., in cancer) or induction/activation to enhance vasodilatory and anti-inflammatory effects (e.g., in cardiovascular disease) [1.2.3, 1.4.1, 1.4.3].